Skip to main content
Premium Trial:

Request an Annual Quote

Pangea, Molecular Simulations Integrate Bioinformatics Tools

Premium

OAKLAND, Calif.--Two bioinformatics software providers--Pangea Systems here and Molecular Simulations of San Diego, Calif.--have agreed to integrate certain elements of their respective product lines to enhance both bioinformatics packages. The companies will use Pangea's application programming interface to link the company's data management system with Molecular Simulations' WebLab Gene Explorer application. Gene Explorer is a graphical environment for analyzing and viewing DNA and protein sequences and structures.

According to the companies, the collaboration will give Gene Explorer users a single point of access to five major public databases and any proprietary data they add to their systems. This should accelerate the drug discovery process, they predicted. In addition, the two firms will investigate establishing links between Pangea's data management system and Molecular Simulations' line of chemical and structural analysis applications for drug discovery.

Filed under

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.